Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Toggle navigation
Contact Us
Subscribe
Promote Your Event
e-Edition
Privacy Policy
Terms of Service
Local Weather
Home Delivery
Submission Forms
News
Local News
The Leader
Heartland News
Sports
Entertainment
Local Events
Multimedia
Photo Galleries
Videos
Obituaries
Classifieds
Real Estate
Property for Rent
Cars & Vehicles
Jobs
Items for Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place an ad
Legals
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Vistagen
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes
June 07, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at Jefferies 2023 Global Healthcare Conference
June 06, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Announces Stockholder-Approved Reverse Stock Split
June 06, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
June 01, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
May 30, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health
May 24, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference
April 19, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Receives New European Patent for AV-101
April 06, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
FDA Provides Positive Feedback to Vistagen Regarding Use of the Liebowitz Social Anxiety Scale (LSAS) as an Endpoint in Phase 3 Development of Fasedienol (PH94B) for Treatment of Social Anxiety Disorder
March 30, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder
March 22, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder
March 08, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at Cowen 43rd Annual Health Care Conference
March 02, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine
March 01, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results
February 07, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023
February 06, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition
February 02, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder
January 24, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety
January 10, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder
December 30, 2022
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Acquire Pherin Pharmaceuticals
December 21, 2022
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder
December 06, 2022
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder
November 30, 2022
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease
November 17, 2022
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Reports Second Quarter Financial Results and Provides Corporate Update
November 10, 2022
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022
November 04, 2022
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at Stifel 2022 Healthcare Conference
November 03, 2022
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Host Concordia Live Webinar on Mental Health with Leaders from McKinsey Health Institute, WEVO, and In KidZ
October 26, 2022
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Participate at Cantor Neurology & Psychiatry Conference
October 03, 2022
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen CEO Shawn Singh to Join Executive Roundtable Discussing Mental Health at Concordia Annual Summit
September 20, 2022
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Presents Poster at Psych Congress 2022 Highlighting Effect of PH94B on Nasal Electrogram Responses and Biomarkers of Autonomic Nervous System Activity in Healthy Human Subjects
September 19, 2022
From
Vistagen
Via
Business Wire
Tickers
VTGN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.